


AB-101a Phase 2a Clinical Trial Complete Atopic Dermatitis

Anti-inflammatory and Safety Data



Test	AB-101 Result	Test	AB-101 Result		
Mutagenicity ¹	Negative	Chronic Toxicity ¹	Negative		
Carcinogenicity ¹	Negative	Cardiotoxicity ¹	Negative		
Irritation 1	Negative	Respiratory Toxicity ¹	Negative		
Hypersensitivity ¹	Negative	Genotoxicity ¹	Negative		
Photosensitivity ¹	Negative	Reproductive Toxicity ¹	Negative		
Oral Pharmacokinetics ¹	Not Absorbed	Invitro Cytochrome P450 ¹	Negative		
Oral Maximally Tolerated Dose ¹	Negative	Tissue Penetration ²	Minimal		
Acute 30-day Toxicity ¹	Negative	Tissue Sequestration ²	Minimal with Excretion Profile		





Skin Penetration, Capture and Absorption Data

1010 Enniced Ski	rreneu	ration & Capture	1a Negligible Absorption in					
LogP Values and Dru	ug Profile ^{1, 2}	with AB-101 LogP Value ³	Drug Product Absorption in Intact Skin	AB-101 Bio-active 1 ²	AB-101 Bio-active 2	AB-101 Bio-active 3	AB-101 Bio-active 4	AB Bio-ac
	LogP	-1.0 to 2.0	Baseline	100.0%	100.0%	100.0%	100.0%	100.0
	Value ^{1, 2}		Epidermis Amount	0.0%	0.0%	0.0%	0.0%	0.0
	value		Dermis Amount	0.8%	3.8%	1.8%	1.4%	1.3
		 Limited permeability 	Transdermal Amount	0.0%	0.6%	0.7%	0.2%	0.1
	LogP	 Poor lipid solubility 						
Drug	Profile 1, 2	 Poor skin absorption anddistribution 		AB-101	AB-101	AB-101	AB-101	AB
51451	Tome	 Not captured inskin 	Drug Product Absorption in <u>Superficial Wounds</u>	Bio-active 1 ²	Bio-active 2	Bio-active 3	Bio-active 4	² Bio-a
		Metabolized or excreted	Baseline	100.0%	100.0%	100.0%	100.0%	100.0
	LogP AB-101 ³	- 0.11	Epidermis Amount	0.0%	0.0%	0.0%	0.0%	0.0
			Dermis Amount	0.8%	3.8%	1.8%	1.4%	1.3
			Transdermal Amount	0.0%	0.6%	0.7%	0.2%	0.1



Improving

Therapy for Skin Diseases [®]